Somatostatin regulates intracellular signaling in human carotid endothelial cells

被引:21
作者
Badway, AC [1 ]
West, FM [1 ]
Tente, SM [1 ]
Blake, AD [1 ]
机构
[1] Seton Hall Univ, Dept Biol, S Orange, NJ 07079 USA
关键词
somatostatin; somatostatin receptors; inflammation; intercellular adhesion molecules; extracellular regulated kinase; tyrosine phosphatase;
D O I
10.1016/j.bbrc.2004.05.110
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Somatostatin (somatotropin release inhibitory factor; SRIF) is an endogenous peptide produced at sites of inflammation, making the SRIF a candidate in regulating vascular inflammation. We have used primary human coronary artery endothelial cells (hCAEC) as a model to study SRIF's vascular actions. RT-PCR analysis of hCAEC total mRNA demonstrated the presence of the sst(4) receptor subtype, providing a target for SRIF intracellular signaling. Western blotting with phospho-specific ERK1/2 antibodies showed that SRIF-14 acutely inhibited basal phosphorylation of the extracellular regulated kinases (ERK1/2) by 80%. In addition, SRIF-14 treated hCAEC cell lysates showed a 2.6-fold increase in phosphatase activity, which was inhibited by sodium vanadate. Furthermore, SRIF-14 appeared to be anti-inflammatory in hCAEC as IL-1beta-induced adhesion molecule expression was reduced by 50%. Together, these results show that the coronary artery endothelium is a direct target of SRIF action. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1222 / 1227
页数:6
相关论文
共 23 条
[1]
Aplin AE, 1998, PHARMACOL REV, V50, P197
[2]
HYPOTHALAMIC POLYPEPTIDE THAT INHIBITS SECRETION OF IMMUNOREACTIVE PITUITARY GROWTH-HORMONE [J].
BRAZEAU, P ;
VALE, W ;
BURGUS, R ;
LING, N ;
BUTCHER, M ;
RIVIER, J ;
GUILLEMIN, R .
SCIENCE, 1973, 179 (4068) :77-79
[3]
Mammalian MAP kinase signalling cascades [J].
Chang, LF ;
Karin, M .
NATURE, 2001, 410 (6824) :37-40
[4]
Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus [J].
Clemens, A ;
Klevesath, MS ;
Hofmann, M ;
Raulf, F ;
Henkels, M ;
Amiral, J ;
Seibel, MJ ;
Zimmermann, J ;
Ziegler, R ;
Wahl, P ;
Nawroth, PP .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (10) :1236-1240
[5]
The diversity of endothelial cells: a challenge for therapeutic angiogenesis [J].
Conway, EM ;
Carmeliet, P .
GENOME BIOLOGY, 2004, 5 (02)
[6]
Effect of endothelial and adventitial injury on somatostatin receptor expression [J].
Curtis, SB ;
Chen, JC ;
Winkelaar, G ;
Turnbull, RG ;
Hewitt, J ;
Buchan, AMJ ;
Hsiang, YN .
SURGERY, 2000, 127 (05) :577-583
[7]
Somatostatin receptor subtype expression and function in human vascular tissue [J].
Curtis, SB ;
Hewitt, J ;
Yakubovitz, S ;
Anzarut, A ;
Hsiang, YN ;
Buchan, AMJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2000, 278 (06) :H1815-H1822
[8]
Dezsi L, 1996, PHYSIOL RES, V45, P291
[9]
Elliott DE, 1998, J IMMUNOL, V160, P3997
[10]
Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities [J].
Florio, T ;
Morini, M ;
Villa, V ;
Arena, S ;
Corsaro, A ;
Thellung, S ;
Culler, MD ;
Pfeffer, U ;
Noonan, DM ;
Schettini, G ;
Albini, A .
ENDOCRINOLOGY, 2003, 144 (04) :1574-1584